SequelSEC

Gossamer Bio, Inc. GOSS

Pharmaceutical Preparations · CIK 0001728117 · Fiscal year ends 1231

AnnualQuarterlyTTM
Revenue
$48.47M
Fiscal year ended 2025-12-31
Operating income
-$170.73M
Fiscal year ended 2025-12-31
Free cash flow
-$171.34M
Fiscal year ended 2025-12-31

Gossamer Bio, Inc. (GOSS) reported revenue of $48.47M and net income of -$170.37M for the fiscal year ended 2025-12-31. This page shows 4 annual periods of income statement, balance sheet and cash flow figures normalized from Gossamer Bio, Inc.’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Pharmaceutical Preparations.

Income

Gossamer Bio, Inc. income by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-312022-12-31
Revenue$48.47M$114.70M$0$0
Cost of revenueUnavailableUnavailableUnavailableUnavailable
Gross profitUnavailableUnavailableUnavailableUnavailable
Operating income-$170.73M-$59.92M-$183.76M-$218.59M
Net income-$170.37M-$56.53M-$179.82M-$229.38M
Research & developmentUnavailableUnavailableUnavailableUnavailable
Weighted-average diluted sharesshares 228.52Mshares 226.23Mshares 152.62Mshares 84.57M
Pretax income-$170.46M-$55.64M-$179.82M-$229.38M
Income tax expense-$88.00K$893.00K$0$0
Diluted EPS$-0.75$-0.25$-1.18$-2.71
Selling, general & administrativeUnavailableUnavailableUnavailableUnavailable
General & administrative$37.63M$36.13M$38.46M$47.61M
Selling & marketingUnavailableUnavailableUnavailableUnavailable

Balance

Gossamer Bio, Inc. balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-312022-12-31
Cash & equivalents$37.73M$46.07M$32.11M$111.97M
Total assets$172.25M$315.29M$311.92M$272.45M
Current assets$167.64M$309.89M$306.52M$261.88M
Total liabilities$295.01M$285.80M$249.15M$260.37M
Current liabilities$63.44M$45.01M$51.60M$49.23M
Total equity incl. NCI-$122.76M$29.49M$62.77M$12.08M
Temporary (mezzanine) equityUnavailableUnavailableUnavailableUnavailable
InventoryUnavailableUnavailableUnavailableUnavailable
Accounts receivable$12.23M$5.34M$0Unavailable
GoodwillUnavailableUnavailableUnavailableUnavailable
Long-term debtUnavailable$0$814.00K$11.99M
Accounts payable$5.96M$2.32M$5.53M$1.46M

Cash flow

Gossamer Bio, Inc. cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-312022-12-31
Operating cash flow-$171.27M-$3.47M-$159.16M-$187.03M
Capital expenditures$79.00K$0$0$410.00K
Investing cash flow$156.36M$29.02M-$110.97M-$1.04M
Financing cash flow$6.42M-$11.49M$190.15M$117.09M
Net change in cash-$8.34M$13.96M-$79.86M-$71.49M
Stock-based compensation$10.56M$20.62M$28.52M$42.55M
Common dividends paidUnavailableUnavailableUnavailableUnavailable
Common share repurchasesUnavailableUnavailableUnavailableUnavailable
Depreciation & amortization$24.00K$833.00K$1.61M$1.83M

Derived

Gossamer Bio, Inc. derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-312022-12-31
Free cash flow-$171.34M-$3.47M-$159.16M-$187.44M
Gross marginUnavailableUnavailableUnavailableUnavailable
Operating margin-352.2%-52.2%UnavailableUnavailable
FCF margin-353.5%-3.0%UnavailableUnavailable
SBC / revenue21.8%18.0%UnavailableUnavailable
Current ratio2.64x6.88x5.94x5.32x
Revenue YoY growth-57.7%UnavailableUnavailableUnavailable
Net margin-351.5%-49.3%UnavailableUnavailable
R&D / revenueUnavailableUnavailableUnavailableUnavailable
CapEx / revenue0.2%0.0%UnavailableUnavailable
Long-term debt / equityUnavailableUnavailableUnavailableUnavailable
Effective tax rateUnavailableUnavailableUnavailableUnavailable

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open GOSS in the interactive workspace to inspect any figure back to its filing.

Source filings

10-Q · Filed 2026-08-13View SEC filing
10-Q · Filed 2026-05-15View SEC filing
10-K · Filed 2026-03-17View SEC filing
10-Q · Filed 2025-11-05View SEC filing
10-Q · Filed 2025-08-05View SEC filing
10-Q · Filed 2025-05-15View SEC filing

Companies in the same industry

AAGH AARD ABBV ABCL ABEO ABT ABUS ABVC ACAD ACET ACRS ACRV

Every accounting identity this site checks — the balance sheet, the gross profit bridge and the cash flow statement — reconciles in every period shown.